Q1 Earnings Estimate for KALA BIO Issued By HC Wainwright

KALA BIO, Inc. (NASDAQ:KALA) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of KALA BIO in a research note issued to investors on Friday, May 23rd. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of ($1.09) for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for KALA BIO’s current full-year earnings is ($10.84) per share. HC Wainwright also issued estimates for KALA BIO’s Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($0.90) EPS and Q4 2026 earnings at ($0.82) EPS.

KALA BIO Stock Down 1.2%

Shares of NASDAQ KALA opened at $4.04 on Monday. KALA BIO has a 12-month low of $2.92 and a 12-month high of $11.20. The stock’s fifty day simple moving average is $4.20 and its two-hundred day simple moving average is $6.18. The stock has a market capitalization of $26.07 million, a PE ratio of -0.32 and a beta of -1.91. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings data on Friday, March 28th. The company reported ($1.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.28) by $0.54.

Institutional Investors Weigh In On KALA BIO

Institutional investors have recently added to or reduced their stakes in the stock. Readystate Asset Management LP purchased a new position in KALA BIO in the first quarter valued at about $243,000. Geode Capital Management LLC grew its stake in KALA BIO by 28.4% in the fourth quarter. Geode Capital Management LLC now owns 47,642 shares of the company’s stock valued at $331,000 after purchasing an additional 10,526 shares during the last quarter. AIGH Capital Management LLC purchased a new position in KALA BIO in the fourth quarter valued at about $842,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in KALA BIO by 10.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 178,934 shares of the company’s stock valued at $1,242,000 after purchasing an additional 16,271 shares during the last quarter. Finally, Woodline Partners LP purchased a new position in KALA BIO in the first quarter valued at about $1,483,000. Institutional investors own 24.61% of the company’s stock.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.